Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416609 | 1.00 | PARP1 (0.49) | PARP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22749367 | 0.86 | PDE4A (0.46) | PARP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL686704 | 0.86 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL27461883 | 0.79 | PARP1 (0.49) | PARP1EGFRADRB2NCF1ABCG2 | |
| SCHEMBL26313476 | 0.79 | PARP1 (0.49) | PARP1EGFRADRB2NCF1ABCG2 | |
| SCHEMBL26090047 | 0.79 | PARP1 (0.49) | PARP1EGFRADRB2NCF1ABCG2 | |
| SCHEMBL8809376 | 0.79 | PARP1 (0.49) | PARP1EGFRADRB2NCF1ABCG2 | |
| SCHEMBL29461277 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL856547 | 0.76 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DEGFR | |
| SCHEMBL29878151 | 0.75 | ADRB2 (0.51) | PARP1ADRB2NCF1MAOBSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025067384-A1 | AMINO ACID INTEGRIN INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都微芯药业有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-117986260-A | Spiro compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-05-07 | — | — | CN | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| CN-101341133-A | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | ASTRAZENECA AB (SE) | 2009-01-07 | — | — | CN | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-4808715-A | HYPERTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1989-02-28 | — | — | US | disclosed |
| US-4734510-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1988-03-29 | — | — | US | disclosed |
| US-4640920-A | HYPOTENSIVE AGENTS | JOHN WYETH & BROTHER LIMITED (GB) | 1987-02-03 | — | — | US | disclosed |
| US-4464375-A | ANALGESIC, ANTIINFLAMMATORY | SANKYO CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4322420-A | Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PARP1 2347/4885PDE4A 1259/4885PDE4B 1027/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PARP1 3007/4885PDE4A 3891/4885PDE4B 3849/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PARP1 3318/4885PDE4A 3921/4885PDE4B 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.